Abstract:Interferon (IFN) induced activities are critical, early determinants of immune responses and infection outcomes. A key facet of IFN responses is the upregulation of hundreds of mRNAs termed interferon-stimulated genes (ISGs) that activate intrinsic and cell-mediated defenses. While primary interferon signaling is well-delineated, other layers of regulation are less explored but implied by aberrant ISG expression signatures in many diseases in the absence of infection. Consistently, our examination of tonic ISG levels across uninfected human tissues and individuals revealed three ISG subclasses. As tissue identity and many comorbidities with increased virus susceptibility are characterized by differences in metabolism, we characterized ISG responses in cells grown in media known to favor either aerobic glycolysis (glucose) or oxidative phosphorylation (galactose supplementation). While these conditions over time had a varying impact on the expression of ISG RNAs, the differences were typically greater between treatments than between glucose/galactose. Interestingly, extended interferon-priming led to divergent expression of two ISG proteins: upregulation of IRF1 in IFN-γ/glucose and increased IFITM3 in galactose by IFN-α and IFN-γ. In agreement with a hardwired response, glucose/galactose regulation of interferon-γ induced IRF1 is conserved in unrelated mouse and cat cell types. In galactose conditions, proteasome inhibition restored interferon-γ induced IRF1 levels to that of glucose/interferon-γ. Glucose/interferon-γ decreased replication of the model poxvirus vaccinia at low MOI and high MOIs. Vaccinia replication was restored by IRF1 KO. In contrast, but consistent with differential regulation of IRF1 protein by glucose/galactose, WT and IRF1 KO cells in galactose media supported similar levels of vaccinia replication regardless of IFN-γ priming. Also associated with glucose/galactose is a seemingly second block at a very late stage in viral replication which results in reductions in herpes- and poxvirus titers but not viral protein expression. Collectively, these data illustrate a novel layer of regulation for the key ISG protein, IRF1, mediated by glucose/galactose and imply unappreciated subprograms embedded in the interferon response. In principle, such cellular circuitry could rapidly adapt immune responses by sensing changing metabolite levels consumed during viral replication and cell proliferation. Early host responses shape virus infection outcomes. Essential and early responses are mediated by signaling initiated by immune cues termed interferons. While the primary steps of activating these immune signaling pathways are well-studied, it is less clear how secondary signals impact antiviral defenses. Modifiers of the immune response are typically viewed as actors that influence the magnitude of the response and output. Metabolism has been implicated in the regulation of antiviral responses in normal and disease contexts; yet, the roles are incompletely understood particularly in non-immune cells. These studies show that metabolic rewiring results in decreased replication of the model poxvirus vaccinia by selectively increasing levels of a key antiviral protein. These data suggest that metabolites might function as secondary cues to alter the composition of the antiviral response to tip infection outcomes. These findings may have relevance for sensing the success of viral replication and shed light on factors contributing to the poor infection outcomes associated with metabolic diseases considered comorbidities.

Inhibitors of the Interferon Response Enhance Virus Replication In Vitro

Relative Timing of Type I Interferon Response and Virus Replication Determines Disease Outcome During Respiratory Virus Infection

Interferon-Stimulated Genes as Enhancers of Antiviral Innate Immune Signaling

The evolving role of interferons in viral eradication strategies

Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity

Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types

Metabolic reprogramming tips vaccinia virus infection outcomes by stabilizing interferon-g induced IRF1

Interferon-Induced Proteins with Tetratricopeptide Repeats 1 and 2 Are Cellular Factors That Limit Hepatitis B Virus Replication

An orally available, small-molecule interferon inhibits viral replication

The Antiviral Activity of Interferon-Induced Transmembrane Proteins and Virus Evasion Strategies

[Investigating the Inhibitory Effects of Interferon-Alpha on the Replication of Hepatitis C Virus Replicon].

The Interferon-Induced Protein with Tetratricopeptide Repeats Repress Influenza Virus Infection by Inhibiting Viral RNA Synthesis

Enhancement of rAAV titers via inhibition of the interferon signaling cascade in transfected HEK293 suspension cultures

Functional Involvement of Interferon-Inducible Transmembrane Proteins in Antiviral Immunity

Metabolic reprogramming tips vaccinia virus infection outcomes by stabilizing interferon-γ induced IRF1

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway

Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway

Interferon Inhibition Enhances the Pilot-Scale Production of Rabies Virus in Human Diploid MRC-5 Cells

Crosstalk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication

IN VITRO INfIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α

Paramyxovirus strategies for evading the interferon response